

Hyemin Jang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8689981/publications.pdf>

Version: 2024-02-01

126
papers

1,475
citations

430442

18
h-index

454577

30
g-index

146
all docs

146
docs citations

146
times ranked

2195
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using ¹⁸ F-AV1451 Positron Emission Tomography Imaging. <i>JAMA Neurology</i> , 2018, 75, 999.	4.5	85
2	The Cortical Neuroanatomy Related to Specific Neuropsychological Deficits in Alzheimer's Continuum. <i>Dementia and Neurocognitive Disorders</i> , 2019, 18, 77.	0.4	85
3	<i>O</i> -GlcNAcylation ameliorates the pathological manifestations of Alzheimer's disease by inhibiting necroptosis. <i>Science Advances</i> , 2021, 7, .	4.7	68
4	Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 154.	3.0	57
5	Total MRI Small Vessel Disease Burden Correlates with Cognitive Performance, Cortical Atrophy, and Network Measures in a Memory Clinic Population. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1485-1497.	1.2	55
6	Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 432-442.	3.3	51
7	Optical coherence tomography angiography as a potential screening tool for cerebral small vessel diseases. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 73.	3.0	44
8	Correlations between Gray Matter and White Matter Degeneration in Pure Alzheimer's Disease, Pure Subcortical Vascular Dementia, and Mixed Dementia. <i>Scientific Reports</i> , 2017, 7, 9541.	1.6	39
9	A Nomogram for Predicting Amyloid PET Positivity in Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 681-691.	1.2	38
10	Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2020, 16, 1504-1514.	0.4	35
11	Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke. <i>Journal of Oncology</i> , 2015, 2015, 1-6.	0.6	33
12	Clinical significance of amyloid β positivity in patients with probable cerebral amyloid angiopathy markers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1287-1298.	3.3	31
13	Prediction Model of Conversion to Dementia Risk in Subjects with Amnesic Mild Cognitive Impairment: A Longitudinal, Multi-Center Clinic-Based Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1579-1587.	1.2	30
14	Amyloid involvement in subcortical regions predicts cognitive decline. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2368-2376.	3.3	30
15	Prognostic value of amyloid PET scan in normal pressure hydrocephalus. <i>Journal of Neurology</i> , 2018, 265, 63-73.	1.8	28
16	Frontal-executive dysfunction affects dementia conversion in patients with amnesic mild cognitive impairment. <i>Scientific Reports</i> , 2020, 10, 772.	1.6	27
17	Appropriate reference region selection of 18F-florbetaben and 18F-flutemetamol beta-amyloid PET expressed in Centiloid. <i>Scientific Reports</i> , 2020, 10, 14950.	1.6	24
18	A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1938-1948.	3.3	23

#	ARTICLE	IF	CITATIONS
19	Intrathecal Injection in a Rat Model: A Potential Route to Deliver Human Wharton's Jelly-Derived Mesenchymal Stem Cells into the Brain. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1272.	1.8	22
20	Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. <i>NeuroImage: Clinical</i> , 2019, 24, 101941.	1.4	21
21	Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals. <i>Scientific Reports</i> , 2019, 9, 1814.	1.6	21
22	Predicting amyloid positivity in patients with mild cognitive impairment using a radiomics approach. <i>Scientific Reports</i> , 2021, 11, 6954.	1.6	20
23	Strictly Lobar Microbleeds Reflect Amyloid Angiopathy Regardless of Cerebral and Cerebellar Compartments. <i>Stroke</i> , 2020, 51, 3600-3607.	1.0	19
24	Amyloid Positivity in the Alzheimer/Subcortical-Vascular Spectrum. <i>Neurology</i> , 2021, 96, e2201-e2211.	1.5	19
25	Body Mass Index and Mortality Rate in Korean Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 399-406.	1.2	18
26	Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal men. <i>European Journal of Neurology</i> , 2016, 23, 110-119.	1.7	18
27	Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments. <i>Scientific Reports</i> , 2020, 10, 19576.	1.6	18
28	Hearing loss is associated with cortical thinning in cognitively normal older adults. <i>European Journal of Neurology</i> , 2020, 27, 1003-1009.	1.7	18
29	Trajectories of Physiological Brain Aging and Related Factors in People Aged from 20 to over-80. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1237-1246.	1.2	17
30	The Effects of Longitudinal White Matter Hyperintensity Change on Cognitive Decline and Cortical Thinning over Three Years. <i>Journal of Clinical Medicine</i> , 2020, 9, 2663.	1.0	17
31	Decreased hemoglobin levels, cerebral small-vessel disease, and cortical atrophy: among cognitively normal elderly women and men. <i>International Psychogeriatrics</i> , 2016, 28, 147-156.	0.6	16
32	Amyloid and cerebrovascular burden divergently influence brain functional network changes over time. <i>Neurology</i> , 2019, 93, e1514-e1525.	1.5	16
33	Sex-specific relationship of cardiometabolic syndrome with lower cortical thickness. <i>Neurology</i> , 2019, 93, e1045-e1057.	1.5	16
34	Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 113.	3.0	16
35	Distinct Brain Regions in Physiological and Pathological Brain Aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 147.	1.7	15
36	Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 564.	1.6	15

#	ARTICLE	IF	CITATIONS
37	Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 292-303.	3.3	15
38	Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology: Data from a nationwide registry in Korea. <i>Journal of Neuroimmunology</i> , 2016, 293, 34-38.	1.1	13
39	Cortical atrophy pattern-based subtyping predicts prognosis of amnesic MCI: an individual-level analysis. <i>Neurobiology of Aging</i> , 2019, 74, 38-45.	1.5	13
40	Analysis of dementia-related gene variants in APOE ϵ 4 noncarrying Korean patients with early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 85, 155.e5-155.e8.	1.5	13
41	Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1971-1983.	3.3	13
42	Head-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 281-290.	1.2	13
43	Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. <i>Journal of Korean Medical Science</i> , 2020, 35, e361.	1.1	13
44	Distinctive Clinical Effects of Haemorrhagic Markers in Cerebral Amyloid Angiopathy. <i>Scientific Reports</i> , 2017, 7, 15984.	1.6	12
45	The Impact of APOE ϵ 4 in Alzheimer's Disease Differs According to Age. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1377-1385.	1.2	12
46	Clinical significance of focal β -amyloid deposition measured by 18F-flutemetamol PET. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 6.	3.0	12
47	Disease progression modeling of Alzheimer's disease according to education level. <i>Scientific Reports</i> , 2020, 10, 16808.	1.6	12
48	Performance of the plasma A β 42/A β 40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 179.	3.0	12
49	Distinct amyloid distribution patterns in amyloid positive subcortical vascular cognitive impairment. <i>Scientific Reports</i> , 2018, 8, 16178.	1.6	11
50	Machine Learning for the Prediction of Amyloid Positivity in Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 143-157.	1.2	11
51	The Impact of Amyloid- β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 573-585.	1.2	10
52	Helicobacter Pylori Infection Is Associated with Neurodegeneration in Cognitively Normal Men. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1591-1599.	1.2	10
53	Cortical neuroanatomical changes related to specific neuropsychological deficits in subcortical vascular cognitive impairment. <i>NeuroImage: Clinical</i> , 2021, 30, 102685.	1.4	9
54	Disease progression modelling from preclinical Alzheimer's disease (AD) to AD dementia. <i>Scientific Reports</i> , 2021, 11, 4168.	1.6	9

#	ARTICLE	IF	CITATIONS
55	Distinctive Temporal Trajectories of Alzheimer's Disease Biomarkers According to Sex and APOE Genotype: Importance of Striatal Amyloid. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 829202.	1.7	9
56	Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease. <i>Life</i> , 2022, 12, 275.	1.1	9
57	THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report. <i>BMC Neurology</i> , 2019, 19, 211.	0.8	8
58	Presynaptic dopaminergic function in early-onset Alzheimer's disease: an FP-CIT image study. <i>Neurobiology of Aging</i> , 2020, 86, 75-80.	1.5	8
59	Reduced forced vital capacity is associated with cerebral small vessel disease burden in cognitively normal individuals. <i>NeuroImage: Clinical</i> , 2020, 25, 102140.	1.4	8
60	Prediction of tau accumulation in prodromal Alzheimer's disease using an ensemble machine learning approach. <i>Scientific Reports</i> , 2021, 11, 5706.	1.6	8
61	Finding the optimal cutoff value for amyloid β^2 positivity using the iterative outlier method and concordance rate. <i>Precision and Future Medicine</i> , 0, , .	0.5	8
62	Dopa Responsive Parkinsonism in an Early Onset Alzheimer's Disease Patient with a Presenilin 1 Mutation (A434T). <i>Journal of Alzheimer's Disease</i> , 2019, 71, 7-13.	1.2	7
63	The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 13583.	1.6	7
64	Identifying novel genetic variants for brain amyloid deposition: a genome-wide association study in the Korean population. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 117.	3.0	7
65	Social Event Memory Test (SEMT): A Video-based Memory Test for Predicting Amyloid Positivity for Alzheimer's Disease. <i>Scientific Reports</i> , 2018, 8, 10421.	1.6	6
66	Vascular Effects on Depressive Symptoms in Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 597-605.	1.2	6
67	Prediction of amyloid β^2 PET positivity using machine learning in patients with suspected cerebral amyloid angiopathy markers. <i>Scientific Reports</i> , 2020, 10, 18806.	1.6	6
68	Diagonal Earlobe Crease is a Visible Sign for Cerebral Small Vessel Disease and Amyloid- β^2 . <i>Scientific Reports</i> , 2017, 7, 13397.	1.6	5
69	Differences in neuroimaging features of early- versus late-onset nonfluent/agrammatic primary progressive aphasia. <i>Neurobiology of Aging</i> , 2020, 86, 92-101.	1.5	5
70	Identifying a subtype of Alzheimer's disease characterised by predominant right focal cortical atrophy. <i>Scientific Reports</i> , 2020, 10, 7256.	1.6	5
71	¹⁸ F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β^2 -Amyloid-Negative Amnesic Mild Cognitive Impairment. <i>Yonsei Medical Journal</i> , 2022, 63, 259.	0.9	5
72	Intracerebroventricular Administration of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Induces Transient Inflammation in a Transgenic Mouse Model and Patients with Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 563.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Multimodal imaging analyses in patients with genetic and sporadic forms of small vessel disease. <i>Scientific Reports</i> , 2019, 9, 787.	1.6	4
74	Association between APOE ϵ 2 and ϵ 4 burden in patients with Alzheimer- and vascular-type cognitive impairment. <i>Neurology</i> , 2020, 95, e2354-e2365.	1.5	4
75	Cognitive trajectories of patients with focal A β -amyloid deposition. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 48.	3.0	4
76	Effect of education on functional network edge efficiency in Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 17255.	1.6	4
77	Amyloid Positive Hydrocephalus: A Hydrocephalic Variant of Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1467-1479.	1.2	3
78	Exploring the Potential of Mesenchymal Stem Cell-Based Therapy in Mouse Models of Vascular Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5524.	1.8	2
79	Heterogeneous Disease Progression in a Mouse Model of Vascular Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2820.	1.8	2
80	Independent effects of amyloid and vascular markers on long-term functional outcomes: An 8-year longitudinal study of subcortical vascular cognitive impairment. <i>European Journal of Neurology</i> , 2021, , .	1.7	2
81	Development of prediction models for distinguishable cognitive trajectories in patients with amyloid positive mild cognitive impairment. <i>Neurobiology of Aging</i> , 2022, , .	1.5	2
82	Intraspinal Cavity Injection of Human Mesenchymal Stem Cells and Tracking their Migration into the Rat Brain. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	1
83	Harmonisation of PET imaging features with different amyloid ligands using machine learning-based classifier. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 321-330.	3.3	1
84	A Case of Early-Onset Alzheimer's Disease Mimicking Schizophrenia in a Patient with Presenilin 1 Mutation (S170P). <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1025-1031.	1.2	1
85	Clinical Characteristic in Primary Progressive Aphasia in Relation to Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 633-645.	1.2	1
86	P4196: Clinical Impacts of Cortical Superficial Siderosis in Patients With Clinically Diagnosed Cerebral Amyloid Angiopathy. <i>Alzheimer's and Dementia</i> , 2016, 12, P1099.	0.4	0
87	[P1224]: ¹⁸ F-AV1451 PET IMAGING IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P329.	0.4	0
88	[P2406]: IN VIVO BRAAK STAGING OF AMNESTIC MCI USING ¹⁸ F-THK5351 PET IMAGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P786.	0.4	0
89	[P2407]: PREVALENCE OF AMYLOID-PET POSITIVITY ACCORDING TO AGE AND APOE GENOTYPE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P787.	0.4	0
90	[P2424]: PROTECTIVE EFFECTS OF EDUCATION ON THK5351 UPTAKES IN MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON-ALZHEIMER PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2017, 13, P798.	0.4	0

#	ARTICLE	IF	CITATIONS
91	[P3â€“194]: DIAGONAL EARLOBE CREASE, CEREBRAL SMALL VESSEL DISEASE, AND BETAâ€“AMYLOIDOSIS IN COGNITIVELY IMPAIRED PATIENTS. Alzheimer's and Dementia, 2017, 13, P1009.	0.4	0
92	[P3â€“258]: TRAJECTORIES OF COGNITIVE DECLINE IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1042.	0.4	0
93	[P3â€“337]: THK5351 UPTAKES IN EARLY AND LATE STAGES OF AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1082.	0.4	0
94	[P3â€“413]: CLINICAL EFFECT OF SMALLâ€“VESSEL DISEASE AND WHITE MATTER NETWORK ON DEPRESSION IN PATIENTS WITH COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1124.	0.4	0
95	[P4â€“169]: COGNITIVE TRAJECTORIES IN PATIENTS WITH NONâ€“AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2017, 13, P1326.	0.4	0
96	[P1â€“423]: THE DEVELOPMENT OF AN ALZHEIMER'S DISEASE RISK SCORE BASED ON THE CORTICAL THICKNESS ANALYSES. Alzheimer's and Dementia, 2017, 13, P440.	0.4	0
97	[P1â€“428]: NONâ€“ALCOHOLIC FATTY LIVER DISEASE AND CEREBRAL SMALLâ€“VESSEL DISEASE IN COGNITIVELY NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P443.	0.4	0
98	[P1â€“454]: POSITIVE ASSOCIATION BETWEEN EDUCATION AND THKâ€“5351 UPTAKES IN PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P460.	0.4	0
99	[P2â€“318]: RISK SCORE FOR THE PREDICTION OF DEMENTIA RISK IN SUBJECTS WITH AMNESTIC MILD COGNITIVE IMPAIRMENT: A LONGITUDINAL, MULTIâ€“CENTER CLINICâ€“BASED STUDY. Alzheimer's and Dementia, 2017, 13, P739.	0.4	0
100	[O4â€“04â€“03]: SYNERGISTIC EFFECT OF TAU, AMYLOID, AND VASCULAR BURDEN ON COGNITIVE DECLINE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2017, 13, P1235.	0.4	0
101	P1â€“382: COMPARISON OF AD PATHOLOGIES IN HYPERTENSIVE SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT AND CEREBRAL AMYLOID ANGIOPATHY. Alzheimer's and Dementia, 2018, 14, P445.	0.4	0
102	P1â€“386: AMYLOID AND CEREBROVASCULAR BURDEN INFLUENCES ON LONGITUDINAL BRAIN FUNCTIONAL CONNECTIVITY CHANGES IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P448.	0.4	0
103	O1â€“14â€“01: PULMONARY FUNCTION AND CEREBRAL SMALL VESSEL DISEASE AND CORTICAL THINNING IN COGNITIVELY NORMAL INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P256.	0.4	0
104	P2â€“319: DISEASE COURSE MODELING OF ALZHEIMER'S DISEASE DEPENDING ON AMYLOID DEPOSITION: AN ACCELERATED LONGITUDINAL DESIGN. Alzheimer's and Dementia, 2018, 14, P804.	0.4	0
105	ICâ€“Pâ€“121: EFFECTS OF CARDIOMETABOLIC RISK FACTORS ON BRAIN AGING IN THE ELDERLY. Alzheimer's and Dementia, 2018, 14, P102.	0.4	0
106	P1â€“407: ALZHEIMER'S DISEASE WITH RIGHT FOCAL CORTICAL ATROPHY. Alzheimer's and Dementia, 2018, 14, P459.	0.4	0
107	ICâ€“Pâ€“078: CLINICAL SIGNIFICANCE OF A/T/N SYSTEM IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT PATIENTS. Alzheimer's and Dementia, 2018, 14, P69.	0.4	0
108	P3â€“393: A NOMOGRAM FOR PREDICTING AMYLOID PET POSITIVITY IN AMNESTIC MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P1248.	0.4	0

#	ARTICLE	IF	CITATIONS
109	O1â€14â€03: NATURAL HISTORY OF SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT: AN 8.5â€YEAR LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P258.	0.4	0
110	P1â€483: COGNITIVE RESERVE AND EFFICIENCY NETWORK: IN NORMAL COGNITION, AMNESTIC MCI AND ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2018, 14, P511.	0.4	0
111	P3â€346: CLINICAL SIGNIFICANCE OF AMYLOID BETA POSITIVITY IN PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY MARKERS. Alzheimer's and Dementia, 2018, 14, P1216.	0.4	0
112	ICâ€Pâ€050: AMYLOID DEPOSITION IN THE SUBCORTICAL REGION PREDICTS COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, P49.	0.4	0
113	P3â€425: ALZHEIMER'S DEMENTIA CONVERSION IN AMNESTIC MCI ACCORDING TO NEUROPSYCHOLOGICAL PROFILE. Alzheimer's and Dementia, 2018, 14, P1272.	0.4	0
114	Clinical Effects of Frontal Behavioral Impairment: Cortical Thickness and Cognitive Decline in Individuals with Subjective Cognitive Decline and Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 69, 213-225.	1.2	0
115	The effect of smartphone appâ€based cognitive training on cognition in communityâ€dwelling elderly: A randomized controlled trial. Alzheimer's and Dementia, 2020, 16, e039268.	0.4	0
116	Optical coherence tomography angiography in cognitively impaired patients: Vascular and neurodegenerative perspectives. Alzheimer's and Dementia, 2020, 16, e041738.	0.4	0
117	H. pylori infection is associated with cortical thinning in cognitively normal individuals. Alzheimer's and Dementia, 2020, 16, e044295.	0.4	0
118	Thymoma-Associated Paraneoplastic Myositis, Presenting with Rapidly Progressive Muscle		